Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Selenoprotein Synthesis Inhibition and Ferroptosis-Targeting Cancer Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EEFSEC drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EEFSEC Recombinant Protein (Full-Length / GTPase Domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. Available in E. coli or Insect cell systems for optimal folding. |
View EEFSEC Products |
| Gene Delivery | EEFSEC Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression studies. |
View EEFSEC Products |
| Benchmark Ab | Anti-EEFSEC Recombinant Antibody High-affinity sequence-verified positive control for Western Blot, ELISA, and IP. |
View EEFSEC Products |
| Validator | EEFSEC siRNA Set For knockdown verification and phenotypic assays. |
View EEFSEC Products |
| Related Target A | GPX4 Glutathione peroxidase 4, the primary downstream selenoprotein protecting cells from ferroptosis. Inhibiting EEFSEC blocks GPX4 synthesis. |
View GPX4 Products |
| Related Target B | SECISBP2 SECIS-binding protein 2, the essential binding partner of EEFSEC required for selenocysteine incorporation. |
View SECISBP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GTPase Activity Validation | Recombinant active GTPase domain with verified high purity (>95%) and low endotoxin. |
| Protein-Protein Interaction (PPI) Screening | Highly stable EEFSEC and SECISBP2 proteins optimized for TR-FRET and AlphaLISA assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live EEFSEC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EEFSEC therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule inhibitors and RNA therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting the selective vulnerability of therapy-resistant cancer cells to ferroptosis. By blocking the specialized translation machinery required for selenoprotein synthesis, EEFSEC inhibition offers a novel mechanism to deplete GPX4 and induce lipid peroxidation in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (GTPase Inhibitors) | Academic consortia, Biotech startups | Refractory Solid Tumors, Melanoma | Selectivity Assay (Need Mutant vs WT Proteins and EEF1A counter-screening panels) |
| RNA Therapeutics (siRNA/ASO) | Preclinical stage developers | Hepatocellular Carcinoma, Glioblastoma | In vitro knockdown verification (Need high-purity EEFSEC Western Blot reagents and qPCR controls) |
| PPI Inhibitors (EEFSEC-SECISBP2) | Oncology biopharma | Chemotherapy-resistant cancers | High-throughput screening (Need tag-optimized EEFSEC and SECISBP2 partners) |